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Abstract
Aim: Genetic variants on metabolic and transport enzymes are good candidates to explain inter-individual 
differences in response to antipsychotics. The aim of this study is to evaluate and compare the influence of 
the CYP2D6 , CYPC19, CYP1A2  and ABCB1  variants on plasma levels, treatment response and side effects of 
antipsychotics.
Methods: Twenty polymorphisms in selected genes were genotyped in 318 patients diagnosed with schizophrenia, 
schizoaffective or delusional disorder treated with antipsychotics (clozapine, olanzapine, paliperidone, risperidone, 
aripiprazole and quetiapine). Plasma drug levels were determined after 6 weeks of treatment. The Positive and 
Negative Symptoms Scale (PANSS) and UKU scale of side effects were recorded at baseline and after 12 weeks 
of treatment. The effect of gene variants on plasma drug levels, treatment response and adverse effects were 
examined by multinomial regression. 
Results: CYP1A2  was found to be associated with psychic side effects (P  = 0.02), with variants predicting higher 
enzyme activity associated with lower adverse effects, and was the strongest predictor for this adverse effect 
of all the studied factors. Functional variants in CYP  genes were associated with plasma level differences, with 
higher activity variants associated with lower plasma levels. No association with improvement of the condition, as 
measured by the PANSS score, was found in this study.
Conclusion: The results suggest that increased CYP1A2  activity protects against psychic side effects. Few studies 
have evaluated the impact of genetic factors on treatment response or side effects, and only in relation to a 
selection of adverse reactions. These results are a step towards better understanding of the factors behind the 
different aspects of clinical outcomes, such as various adverse effects. 
Keywords: Pharmacogenetics, antipsychotics, CYP1A2 , CYP2C19, CYP2D6 , ABCB1 , drug response, adverse drug 
reactions
INTRODUCTION
Antipsychotic drugs are the mainstay of treatment for severe mental disorders such as schizophrenia and 
bipolar disorders. The treatment response to antipsychotic medications has wide inter-individual variability. 
About 30%-50% do not respond adequately and 50% develop side effects[1]. Pharmacokinetics are expected 
to play an important role in drug response. The effective antipsychotic dose varies among patients, and 
drug response is highly related to plasma levels, as is drug safety[2]. Plasma levels are a direct consequence 
of the administered dose, but variations on pharmacokinetics, namely drug absorption and metabolism, 
introduce an element of uncertainty in plasma levels. At the same time, plasma levels and all processes 
capable of affecting them may modify the dose-dependent fraction of the drug’s response. These processes 
include transport across biological membranes, such as absorption and excretion, and metabolism. 
Individuals with greater metabolism may require higher doses, while those with lower metabolic rates 
might be more prone to the drugs’ adverse effects and need dose reduction[3-7]. With all these variables 
potential predictors of drug response, which of them, or combination of, is the best predictor of clinical 
endpoints, if at all.
Genetic variants are known to influence both drug transport and metabolism. Variants in certain genes 
[i.e., members of the cytochrome (CYP) P450 superfamily, or CYPs] have attracted attention because 
of their potential to influence treatment response. The CYP superfamily of enzymes is responsible for 
the metabolism of most drugs used in medical practice, including psychiatric drugs. The activity of 
the CYP enzymes, as predicted by the allelic variants of the genes encoding for them, can be classified 
into one of five groups: poor, intermediate, normal, rapid or ultrarapid metabolizers. Most psychiatric 
drugs are metabolized by the enzymes CYP2D6, CYP1A2 and CYP2C19. Another potentially important 
gene is ABCB1, which encodes the transport protein MDR1. This protein is expressed in the luminal 
membrane of enterocytes and it can influence the absorption and bioavailability of substrate drugs. 
ABCB1 is also expressed in the blood-brain barrier and can affect penetration into the central nervous 
system[8,9]. Although CYP genetic variants have been widely investigated in relation to mental disorders 
and their treatment, the contribution of ABCB1 to treatment response and its possible interactions with 
CYP functional variants is scarcely known. The identification of factors with greater influence on clinical 
doses and response to psychotropic drugs may have an important effect on the improvement of treatment 
in psychiatry. CYP enzymes can have genetic variation ranging from loss-of-function alleles to full gene 
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duplications, which can have drastic effects on enzymatic activity. The consequences of these variants on 
the plasma levels of drugs have been extensively reported[3,10-12]. The contribution of ABCB1 to plasma 
levels has been investigated, although there is little evidence that this transporter plays a relevant role[6,12,13]. 
However, there are studies that have reported an association between ABCB1 variants and treatment 
response, albeit in moderate sample sizes or healthy volunteers[14]. The number of studies focusing on 
pharmacokinetic parameters vastly outnumbers publications evaluating treatment response and side effects. 
Of these, results on clinical outcomes are unclear. For CYP2D6, there are negative reports[15], although it 
has also been reported that improvement of the condition is affected by the metabolizing phenotype[7,16]. 
The situation is similar for ABCB1, with some studies having found association[17,18] with antipsychotic 
responses while others have not[19]. There have also been reports of association with genetic variation in 
CYPs and ABCB1 with adverse effects[20-23]. These studies focus on particular adverse effects, such as QT 
interval prolongation, dyskinesias and prolactinemia. However, no study has evaluated the impact on a 
wide spectrum of possible adverse effects.
The objective of this study is to evaluate the contribution of genetic variants in CYPs, and ABCB1 genes on 
antipsychotic drug doses, treatment response and induced side effects, in order to select the factors most 
predictive of response. To achieve this objective, data regarding efficacy, side-effects, plasma levels and 
CYPs and ABCB1 genetic variants were collected in a sample of patients treated with antipsychotics. These 
patients were participants of a previous study[24] investigating the efficiency of a pharmacogenetic algorithm 
using the genotype of different CYPs, which concluded that the inclusion of pharmacogenetic information 
was beneficial for treatment. However, plasma levels were not investigated other than for assessing 
adherence, and neither was drug transport or in-depth analysis of adverse effects. 
METHODS
Sample
Three hundred and eighteen patients from a previous work[24] were included in the study. The gender 
distribution was 55% male and 45% female. Mean age was 47 years old. These patients all had a diagnosis 
of schizophrenia, schizoaffective or delusional disorder. The most commonly used drug was clozapine 
(135 patients) followed by olanzapine (41 patients), paliperidone (39 patients), risperidone (38 patients), 
aripiprazole (21 patients), and quetiapine (18 patients); the remaining patients used other drugs. All 
patients used a single antipsychotic for the duration of the study. One hundred and thirty of these patients 
received a pharmacogenetic intervention consisting of adjustment of their antipsychotic drug dose 
according to their CYP genetic profile when required, while the rest received standard treatment. This 
cohort is described in Table 1.
Biochemical parameters
The plasma concentrations of both the antipsychotic and its main metabolite were determined at 6 weeks 
after starting treatment, when steady state was achieved. Since treatment doses were not modified after 
reaching steady state, plasma levels were assumed to be stable for the remainder of the treatment. The 
plasma concentration of parent antipsychotic drugs, metabolites and active moiety were measured by a 
validated high-performance liquid chromatography (HPLC) method, using ultraviolet visible diode array 
detection and solid-phase extraction on cyano cartridges. Compounds were separated on a C8 reversed-
phase column with a gradient of acetonitrile and phosphate buffer 50 mM, pH 3.8 and detected at 210 
and 278 nm. To assure high precision and accuracy of the method, an internal standard was included in 
the sample preparation and quantitative evaluation. The within- and between day precision expressed as 
coefficient of variation (CV)% were < 10%. The quality of analyses was subject to a program of internal 
quality control and external quality assessment[25]. 
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The dose used for each patient was recorded and standardized into olanzapine-equivalent doses between 
the different antipsychotic agents[26]).
Clinical parameters
Clinical progression of patients was evaluated with the Positive and Negative Symptoms Scale (PANSS)[27]. 
Patients were evaluated at the beginning of the study and 12 weeks after treatment. Similarly, the 
development of adverse events was tracked with the UKU side effects rating scale[28] at baseline and again 
at 12 weeks after starting treatment. The UKU scores for different side effects were grouped into four 
categories: psychic, neurologic, autonomic and others. A fifth and final category, total UKU, captures the 
overall emergence of any side effect, as it combines the scores of all UKU categories. 
Genetic profile
Whole blood samples were taken from patients at the beginning of the study. DNA was extracted with 
a commercial kit (QIAmp DNA mini Kit, Qiagen) following the manufacturers recommendations. 
Genotyping of twenty functional polymorphisms in the ABCB1, CYP2C19, CYP1A2 and CYP2D6 genes, 
including copy number variations on the CYP2D6 gene, was performed using iPlex® Gold chemistry and 
the MassARRAY platform (CEGEN-PRB2-ISCIII, University of Santiago de Compostela, Spain). Table 2 
summarizes the polymorphisms investigated and their predicted phenotype. The selected polymorphisms 
in cytochromes led to altered enzymatic activity, ranging from gene duplication related to increased protein 
production to loss of functionial alleles. The polymorphism in ABCB1 (3435C>T) leads to a synonymous 
substitution, however this change has been associated with lower expression, possibly due to linkage with a 
different causal polymorphism or by ribosome stalling, i.e., a less efficient translation by using a less usual 







Major depression 3 0.9%
Brief psychosis 1 0.4%
Delusional disorder 55 17.3%


















Table 1. General information about the study sample
SD: standard deviation; Altered PGX: patients with a non-NM metabolism for the prescribed drug
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codon[29]. For CYPs, genotype information was converted into activity scores, according to Gaedigk et al.[30] 
and adapted to genes other than CYP2D6 using the same criteria. Phenotype imputation based on 
genotype was done according to the latest consensus article published by the Clinical Pharmacogenetics 
Implementation Consortium (CPIC), with the activity score for CYP2D6*10 updated to the 2019 
revision[31,32]. The total activity score for an individual is the result of adding the scores of the two alleles 
they carry for that gene.
After obtaining their genetic profile, 73 of the subjects were found to be carriers of genetic combinations 
that would modify their ability to metabolize the drug they were prescribed. This is represented by 
ultrarapid (UM) for CYP1A2 in patients on clozapine or olanzapine, UM or poor metabolizer (PM) for 
CYP2C19 in clozapine users, and PMs, intermediate metabolizer (IMs) or UMs for CYP2D6 in patients on 
risperidone, aripiprazole, haloperidol, pimozide or trifluoperazine.
Statistical analysis
Multivariate regression analyses of the results were performed using SPSS Statistics v23.0.0.0 (IBM). Plasma 
levels, change in PANSS and in UKU scores were used as dependent variables, with genetic information on 
the different CYPs (CYP1A2, CYP2C19 and CYP2D6) and ABCB1 being the explanatory variables. Gender, 
age, dose, type of antipsychotic and pharmacogenetic intervention were also included as covariates.
RESULTS
The influence of genetic factors on plasma levels was investigated using the different CYPs and ABCB1 as 
predictors, and age, gender, dose, and the intervention arm as covariables. The full sample of 318 patients 
was used in all cases, but to account for the different affinities of the antipsychotics for each protein, the 
interaction between the antipsychotic and CYP1A2, CYP2C19, CYP2D6 and ABCB1 genes was used as a 
predictor. These interactions showed significant association with plasma levels with P-values < 0.001 in all 
cases [Table 3]. The interaction with ABCB1 had roughly the same P-value as CYP1A2 and CYP2C19, while 
Gene Allele designation Allele activity score rsID
CYP1A2 *1F 1.5 rs762551
CYP2C19 *2 0 rs12769205
*17 1.5 rs12248560
CYP2D6 *3 0 rs35742686
*4 0 rs3892097













xN 2 gene duplication
ABCB1 3435C>T Reduced expression rs1045642
Table 2. Activity score for the studied polymorphisms
Activity score: 0-loss of function, 0.25-drastically reduced function, 0.5-reduced function, 1-normal function, 1.5-increased function, 
2-gene duplication, rsID: accession number on the dbSNP database
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being one order of magnitude higher than CYP2D6 (P-values of 1.26 × 10-9, 1.26 × 10-9, 1 × 10-9 and 5.97 × 10-10 
for ABCB1, CYP1A2, CYP2C19 and CYP2D6, respectively).
Regarding change in PANSS scores, none of the studied genetic variants showed a statistically significant 
association, and the models used were not statistically significant either. Regarding the change in UKU 
scores, CYP1A2 models were statistically significant for total UKUs (P = 0.03) and psychic UKUs (P = 
0.014). Of these models, antipsychotic*CYP1A2 resulted in a significant association with psychic UKU 
only (P = 0.007), with higher activity scores being associated with less adverse effects. The mean differences 
in psychic UKU at baseline minus UKU at 12 weeks was 0.67 for Activity Score (AS) = 1 (Normal 
Metabolizers), 2.12 for AS = 1.5 (Rapid Metabolizers) and 2.13 for AS = 2 (Ultrarrapid Metabolizers). This 
association was further explored by comparing the psychic UKU using only the portion of the sample 
treated with the CYP1A2 substrates clozapine and olanzapine, therefore removing the confounding effect of 
other substrates. This association did not change when the antipsychotic class was reduced to the substrates 
LEVELS PANSS T UKU P UKU N UKU A UKU O UKU
CYP1A2
Model P -value 5.05 x 10-8 0.39 0.03 0.01 0.19 0.72 0.08
Age 0.30 0.12 0.22 0.03 0.32 0.94 0.23
Gender 0.20 0.21 0.59 0.92 0.73 0.97 0.39
Dose 0.30 0.31 0.01 0.31 0.03 0.90 0.01
Intervention 0.63 0.96 0.37 0.08 0.85 0.82 0.94
Antipsychotic*CYP1A2 1.26 x 10-9 0.40 0.06 0.01 0.58 0.10 0.75
CYP2C19
Model P -value 3.16 x 10-8 0.43 0.11 0.22 0.09 0.86 0.09
Age 0.45 0.07 0.27 0.03 0.25 0.84 0.25
Gender 0.13 0.22 0.43 0.81 0.68 0.90 0.39
Dose 0.18 0.36 0.01 0.34 0.02 0.91 0.01
Intervention 0.33 0.86 0.63 0.30 0.89 0.63 1
Antipsychotic*CYP2C19 1 x 10-9 0.83 1 0.57 0.29 0.22 0.79
CYP2D6
Model P -value 3.46 x 10-8 0.5 0.08 0.07 0.13 0.75 0.09
Age 0.38 0.17 0.19 0.03 0.28 0.97 0.23
Gender 0.18 0.26 0.61 0.95 0.69 0.97 0.41
Dose 0.24 0.3 0.01 0.31 0.03 0.85 0.01
Intervention 0.56 0.90 0.42 0.1 0.91 0.74 0.87
Antipsychotic*CYP2D6 5.97 x 10-10 0.49 0.29 0.12 0.25 0.11 0.99
ABCB1
Model P -value 3.81 x 10-8 0.44 0.66 0.17 0.12 0.84 0.07
Age 0.30 0.06 0.20 0.03 0.33 0.85 0.19
Gender 0.20 0.33 0.62 0.90 0.84 1 0.56
Dose 0.30 0.50 0.01 0.27 0.02 0.77 0.004
Intervention 0.63 0.91 0.59 0.35 0.97 0.67 0.94
Antipsychotic*ABCB1 1.26 x 10-9 0.63 0.25 0.19 0.55 0.19 0.41
Affected by CYP
Model P -value 3.46 x 10-8 0.22 0.09 0.09 0.05 0.66 0.12
Age 0.97 0.09 0.25 0.02 0.11 0.80 0.16
Gender 0.33 0.1 0.27 0.71 0.43 0.88 0.28
Dose 0.22 0.06 0.01 0.34 0.02 0.79 0.01
Intervention 0.79 0.89 0.52 0.21 1 0.55 0.96
Antipsychotic 6.75 x 10-11 0.73 0.44 0.08 0.11 0.08 0.96
CYPs 0.37 0.59 0.38 0.41 0.62 0.84 0.51
Table 3. Association of genetic factors with levels, response and side effects
P -values for Levels: plasma levels, PANSS: change in PANSS score; T UKU: change in total UKUs, P UKU: change in psychic UKUs; N UKU: 
change in neurologic UKUs, A UKU: change in autonomic UKUs; O UKU: change in other UKUs
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(clozapine and olanzapine) and non-substrates of CYP1A2. Although antipsychotic0*CYP1A2 bordered on 
the significance threshold for total UKU, it was statistically not significant (P = 0.06).
The combined effect of all CYPs was explored using a dichotomic variable representing whether each 
patient had an altered metabolism for the drug they were taking or not. In these tests, the antipsychotic 
was added as a covariable. However, altered metabolism was not found to be associated with plasma levels, 
change in PANSS or change in any of the UKU scores, although the model itself was marginally significant 
in relation to neurologic UKUs (P = 0.05).
DISCUSSION
The aim of this study was to investigate the effects of genetic variants in pharmacokinetic genes on 
clinical endpoints to compare their influence on the outcome of treatment. The effect of metabolism on 
adverse effects was observed for CYP1A2 on psychological UKUs, but not for other clinical endpoints. No 
correlation between any of the investigated genetic factors with PANSS was found.
The association between CYP1A2, CYP2C19, CYP2D6 and ABCB1 and plasma levels, despite the very 
low P-values, may have explanations other than genetic variation. Unlike clinical dose data, which was 
transformed to olanzapine equivalents, plasma levels did not receive any standardizing transformation, and 
since different molecules reach different concentrations in blood, even in normal circumstances, the type 
of antipsychotic that can reach significance by itself, with P-values even lower than those observed for any 
of the antipsychotic-gene interactions, is observed at the end of Table 3. Therefore, the association observed 
with the interaction is most likely driven by the antipsychotic component of the interaction, which would 
be expected to be significant even without a real influence of the genotype. This does not rule out a true 
contribution of metabolism or transport on plasma levels. In fact, there have been numerous reports on the 
association of CYP2D6 with plasma levels of risperidone, aripiprazole, haloperidole, zuclopenthixole, and 
pimozide[3,6,10,11,13,33,34] and CYP1A2 with olanzapine[35], which is consistent with their metabolic pathways. 
For clozapine, the existing data shows a clear association with CYP1A2 activity, including the inducer effect 
of smoking on plasma levels but the effect of genetic variation itself has failed to show an association in 
some studies[36-38]. There are also reports on the association of ACBC1 with plasma levels of aripiprazole and 
quetiapine[39,40]. It should be noted that CYP2D6 had the strongest association, at one order of magnitude 
lower than the other three genes, which could reflect a higher influence.
Regarding changes in PANSS scores, none of the CYPs or ABCB1 genetic variants investigated showed 
any effect. In fact, no predictors of clinical efficacy were found at all in this study. CYPs are expected to be 
related more to side effects than efficacy, because most genetic variations lead to decreased metabolism, 
whereas the lack of efficacy is expected to be observed when metabolism is increased. Studies that have 
addressed the effect of metabolism on efficacy have had contradictory results. A large study by Jukic et al.[3] 
found that both very high and very low CYP2D6 metabolism (PMs or UMs) are predictors for treatment 
switch from risperidone. It should be noted that treatment switching could be due to the lack of efficacy 
but also, from intolerable adverse effects. van de Bilt et al.[15] investigated the possibility that ultrarapid 
metabolism might lead to the lack of improvement, but could not confirm this hypothesis. Regarding 
CYP1A2, the studied polymorphism leads to increased expression, and thus it is reasonable to think 
that carriers would have a lower change in PANSS due to increased metabolism. This was observed by 
Czerwensky et al.[35] reporting an inverse correlation between predicted CYP1A2 activity and improvement 
of symptoms in patients treated with clozapine and olanzapine. Nonetheless, increased metabolism has 
also been described as a factor for good response. Piatkov et al.[41] observed in their clozapine-treated 
cohort that increased metabolism through CYP2C19 leads to a lower risk of diabetes and a higher chance 
of clinical improvement. ABCB1 has also been studied regarding efficacy. Papazisis et al.[17] found an 
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involvement of ABCB1 in the evolution of PANSS, but only in patients with decreased CYP2D6 activity, and 
also only for the rs2032582 (2677G>T/A) polymorphism in ABCB1, but not rs1045642 (3435C>T), which 
is the one used in the present study. Other authors, however, have been able to find an effect of 3435C>T 
on clinical improvement[18,40]. The effect of ABCB1 3435C>T might be limited to specific substrates or apply 
only to haplotypes. 
It was found that CYP1A2 genetic variants were directly associated with changes in psychological UKU. As 
expected, higher CYP1A2 activity is related to less psychological adverse effects due to the dose-dependent 
nature of most adverse drug reactions. The association of CYP1A2 variants with psychological UKUs was 
stronger than that of age, highlighting its importance. While drug dose was associated with UKUs in most 
cases, this was not true for psychological adverse effects, which suggests that metabolic activity is more 
important than the actual dose regarding this class of adverse reactions. Local metabolism in the brain, 
as opposed to liver metabolism, could lead to changes in local exposure not reflected by plasma levels. 
CYP1A2 is expressed in the rat brain, and has also been reported to be expressed in human brains[42,43]. As 
clozapine, a CYP1A2 substrate, is the drug that was used in more patients than any of the other agents, this 
study was better powered to detect differences regarding CYP1A2. It is possible that the lack of significant 
results for other genes is due to the lower relative abundance of substrates for the corresponding pathways. 
It is also expected that dose is related to overall side effects, but this association was not seen for autonomic 
or psychic UKUs. This makes the effect of CYP1A2 on the latter particularly interesting, because it revealed 
a marker for adverse effects that cannot be predicted with dose. Knowing which side effects are most likely 
to happen can help physicians with follow-up of their patients, so that they can focus on psychic adverse 
effects in those patients with lower CYP1A2 activity scores. 
There are some limitations in this study that might have hampered the discovery of other associations. 
While the sample size of the whole study was moderate, it was not possible to divide into groups based on 
medications, as these groups would have been too small. Furthermore, it would have been interesting to 
check the possibility of drug-drug interactions, as some medications are known to be inhibitors or inducers 
or CYPs and/or ABCB1, so a patient can have an actual phenotype that differs from what one would predict 
based on genotype. However, most patients were on antipsychotic monotherapy and concomitant treatment 
should not have significantly affected the results. Other factors such as smoking habits and diet could 
not be considered due to the lack of specific information. Further studies should address these possible 
confounding factors.
In conclusion, there is a possible association between CYP1A2 and psychic adverse effects, which is 
concordant with the known properties of clozapine. This association should be considered preliminary until 
it is confirmed in an independent study. None of the other studied genes showed any effect on treatment, as 
measured by changes in PANSS and UKU scores. These results suggest that patients with higher CYP1A2 
activity would be less likely to experience psychic adverse effects.
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